Evommune announced the dosing of the first patient in a Phase 2b clinical trial for EVO756, an oral MRGPRX2 inhibitor intended for migraine prophylaxis. The global, randomized study will enroll approximately 330 adults with refractory migraine across two active dose arms and placebo for 12 weeks, exploring daily doses up to 100 mg. Top-line data is expected in 2027. Evommune operates as a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases.
